<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the current study, we used a monoclonal antibody-based enzyme-linked immunosorbent assay and bioassay to assess <z:hpo ids='HP_0001909'>leukemia</z:hpo> inhibitory factor (LIF) protein levels, activity, and function in supernatants of 59 adherent layers derived from <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients and from <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="1" pm="."><plain>We demonstrate that biologically active LIF protein is constitutively produced and secreted by cultured bone marrow stromal cells from <z:hpo ids='HP_0000001'>all</z:hpo> of the studied subjects </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, various cytokines can alter endogenous LIF protein levels </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-four h of exposure to recombinant human (rh) interleukin (IL) 4 (100 units/ml) significantly decreased LIF protein levels in adherent layer conditioned media [median base line level, 2.6 ng/ml; range, 1.6-8.0 ng/ml; median post rhIL-4 exposure levels, 1.9 ng/ml; range, 0.9-5.8 ng/ml (n = 7; P = 0.022)] </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, rhIL-1 beta and rh <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha consistently increased LIF protein levels </plain></SENT>
<SENT sid="5" pm="."><plain>In the samples exposed to 50 units/ml rhIL-1 beta, median base line LIF level was 2.6 ng/ml; median post-LIF level was 9.0 ng/ml (n = 8; P = 0.014) </plain></SENT>
<SENT sid="6" pm="."><plain>In the two samples exposed to rh <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (200 units/ml), LIF levels increased from baseline levels of 2.6 and 2.7 ng/ml to postexposure levels of 7.7 and 12.2 ng/ml, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, the presence of LIF may be relevant to both <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant hematopoietic processes as evidenced by: (a) LIF protein levels in adherent layer conditioned media were significantly elevated in samples from patients with a spectrum of <z:hpo ids='HP_0004377'>hematological neoplasms</z:hpo> [<z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>: median level, 3.0 ng/ml (range, 1.6-11.0 ng/ml); <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>: median level, 4.5 ng/ml (range 1.4-15.5 ng/ml); hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>; median level, 3.5 ng/ml (range 2.2-10.3 ng/ml); <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>-<z:hpo ids='HP_0011010'>chronic</z:hpo> phase: median level, 4.35 ng/ml (range 0.3-19.0 ng/ml); and <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>-<z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>: median level, 6.25 ng/ml (range 0.7-20.3 ng/ml)] as compared to samples from <z:mpath ids='MPATH_458'>normal</z:mpath> individuals (median level, 2.0 ng/ml; range, 0.7-4.6 ng/ml; P &lt; 0.05); and (b) in <z:mpath ids='MPATH_458'>normal</z:mpath> controls, in vitro abrogation of endogenous LIF bioactivity by neutralizing antibody decreased the number of committed granulocyte-macrophage hemopoietic progenitors </plain></SENT>
</text></document>